This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics.
Brenna L. Brady, PhD
Advertisement
Articles by Brenna L. Brady, PhD
Advertisement
Latest Updated Articles
- Burden of EPS in Commercial Patients With Schizophrenia Initiating Atypical Antipsychotics
Published: June 3rd 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
3
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
4
Oncology Care Model Promotes High-Quality, Cost-Conscious Cancer Treatment: Sophia Humphreys, PharmD, MHA, BCBBS
5
